Inhibitors of Bruton's tyrosine kinase

Patent metadata

Field	Value
Publication number	US-9193735-B2
Application number	US-201414156247-A
Country	US
Kind code	B2
Filing date	Jan 15, 2014
Priority date	Sep 22, 2006
Publication date	Nov 24, 2015
Grant date	Nov 24, 2015

Abstract

Disclosed herein is a solid oral formulation comprising a therapeutically effective amount of a compound of Formula (A) formulated for release of the compound in the intestine, wherein the compound of Formula (A) has the structure:

First claim

What is claimed is:

1. A solid oral formulation comprising a therapeutically effective amount of a compound of Formula (A) formulated for release of the compound in the intestine, wherein the compound of Formula (A) has the structure:

wherein:
A is N;
R 1 is L 2 -(substituted or unsubstituted heteroaryl), or L 2 -(substituted or unsubstituted aryl), where L 2 is a bond, O, S, —S(═O), —S(═O) 2 , C(═O), -(substituted or unsubstituted C 1 -C 6 alkyl), or -(substituted or unsubstituted C 2 -C 6 alkenyl);
R 2 and R 3 are independently selected from H or lower alkyl;
R 4 is L 3 -X-L 4 -G, wherein,
L 3 is optional, and when present is a bond, optionally substituted or unsubstituted alkyl, optionally substituted or unsubstituted cycloalkyl, optionally substituted or unsubstituted alkenyl, or optionally substituted or unsubstituted alkynyl;
X is optional, and when present is a bond, O, —C(═O), S, —S(═O), —S(═O) 2 , —NH, —NR 9 , —NHC(O), —C(O)NH, —NR 9 C(O), —C(O)NR 9 , —S(═O) 2 NH, —NHS(═O) 2 , —S(═O) 2 NR 9 —, —NR 9 S(═O) 2 , —OC(O)NH—, —NHC(O)O—, —OC(O)NR 9 —, —NR 9 C(O)O—, —CH═NO—, —ON═CH—, —NR 10 C(O)NR 10 —, heteroaryl, aryl, —NR 10 C(═NR 11 )NR 10 —, —NR 10 C(═NR 11 )—, —C(═NR 11 )NR 10 —, —OC(═NR 11 )—, or —C(═NR 11 )O—;
L 4 is optional, and when present is a bond, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycle;
or L 3 , X and L 4 taken together form a nitrogen containing heterocyclic ring;
G is a Michael acceptor;

R 5 is H, halogen, -L 6 -(substituted or unsubstituted C 1 -C 3 alkyl), -L 6 -(substituted or unsubstituted C 2 -C 4 alkenyl), -L 6 -(substituted or unsubstituted heteroaryl), or -L 6 -(substituted or unsubstituted aryl), wherein L 6 is a bond, O, S, —S(═O), S(═O) 2 , NH, C(O), —NHC(O)O, —OC(O)NH, —NHC(O), or —C(O)NH;
R 9 is selected from among H, substituted or unsubstituted lower alkyl, and substituted or unsubstituted lower cycloalkyl;
each R 10 is independently H, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower cycloalkyl; or
two R 10 groups can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring; or
R 10 and R 11 can together form a 5-, 6-, 7-, or 8-membered heterocyclic ring; or
R 11 is selected from H, —S(═O) 2 R 8 , —S(═O) 2 NH 2 , —C(O)R 8 , —CN, —NO 2 , heteroaryl, or heteroalkyl; or a pharmaceutically acceptable solvate, hydrate, or salt thereof.

2. The solid oral formulation of claim 1 , wherein R 2 and R 3 are each H.

3. The solid oral formulation of claim 2 , wherein R 1 is L 2 -substituted aryl; and L 2 is a bond.

4. The solid oral formulation of claim 3 , wherein the compound has the structure of Formula (B):

wherein:
Y is alkyl or substituted alkyl, or a 4-, 5-, or 6-membered cycloalkyl ring;
each R a is independently H, halogen, —CF 3 , —CN, —NO 2 , OH, NH 2 , -L a -(substituted or unsubstituted alkyl), -L a -(substituted or unsubstituted alkenyl), -L a -(substituted or unsubstituted heteroaryl), or -L a -(substituted or unsubstituted aryl), wherein L a is a bond, O, S, —S(═O), —S(═O) 2 , NH, C(O), CH 2 , —NHC(O)O, —NHC(O), or —C(O)NH;
G is a Michael acceptor;
R 12 is H or lower alkyl; or
Y and R 12 taken together form a 4-, 5-, or 6-membered heterocyclic ring; or a
pharmaceutically acceptable solvate, hydrate, or salt thereof.

5. The solid oral formulation of claim 4 , wherein G is an optionally substituted acrylamide, optionally substituted vinyl sulfonamide, or optionally substituted propiolamide.

6. The solid oral formulation of claim 5 , wherein G is an optionally substituted acrylamide.

7. The solid oral formulation of claim 6 , wherein Y and R 12 taken together form a 6-membered heterocyclic ring.

8. The solid oral formulation of claim 1 , wherein the compound of Formula (A) or a pharmaceutically acceptable solvate, hydrate, or salt thereof is released in the small intestine.

9. The solid oral formulation of claim 1 , further comprising at least one coating chosen from enteric coatings and non-enteric differential release coatings.

10. The solid oral formulation of claim 9 , wherein the at least one coating is chosen from an enteric coating.

11. The solid oral formulation of claim 1 , wherein the compound of Formula (A) or a pharmaceutically acceptable solvate, hydrate, or salt thereof is released to a region of the intestine in which the pH is greater than about pH 4.5, greater than about pH 5.0, or greater than about pH 5.5.

12. The solid oral formulation of claim 1 , further comprising at least one pharmaceutically acceptable excipient.

13. The solid oral formulation of claim 1 , wherein the formulation is in the form of a tablet or capsule.

Assignees

• Pharmacyclics Inc
• Pharmacyclics Llc

Inventors

• Honigberg Lee
• Verner Erik
• Pan Zhengying

Classifications

• A61P5/14

  of the thyroid hormones, e.g. T3, T4 · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P7/06

  Antianaemics · CPC title